Recently, selpercatinib (LOXO-292), which selectively targets oncogenic RET alterations, was approved by the FDA in the United States for the treatment of RET-mutant MTC and RET fusion thyroid cancers (Wirth et al. 2020); it has recently also been approved in the United Kingdom in patients resistant or intolerant of the multikinase inhibitors. This evidence concerns the gene RET and medullary thyroid gland carcinoma.